NASDAQ:KZR - Kezar Life Sciences Stock Price, News & Analysis

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences Inc (NASDAQ:KZR) posted its earnings results on Wednesday, August, 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02. View Kezar Life Sciences' Earnings History.

Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Kezar Life Sciences.

3 Wall Street analysts have issued 12-month price targets for Kezar Life Sciences' shares. Their forecasts range from $15.00 to $15.00. On average, they expect Kezar Life Sciences' share price to reach $15.00 in the next year. This suggests a possible upside of 208.0% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Media coverage about KZR stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kezar Life Sciences earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Kezar Life Sciences.

Kezar Life Sciences saw a decrease in short interest in July. As of July 15th, there was short interest totalling 1,117,200 shares, a decrease of 8.6% from the June 15th total of 1,222,400 shares. Based on an average daily trading volume, of 114,400 shares, the days-to-cover ratio is currently 9.8 days. Currently, 10.0% of the company's shares are sold short. View Kezar Life Sciences' Current Options Chain.

Some companies that are related to Kezar Life Sciences include Merus (MRUS), Puma Biotechnology (PBYI), Provention Bio (PRVB), Collegium Pharmaceutical (COLL), Beyondspring (BYSI), Avid Bioservices (CDMO), Corbus Pharmaceuticals (CRBP), MediciNova (MNOV), resTORbio (TORC), AC Immune (ACIU), Mallinckrodt (MNK), Organogenesis (ORGO), Arcus Biosciences (RCUS), BIOFRONTERA AG/ADR (BFRA) and Akorn (AKRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Gilead Sciences (GILD), Apollo Commercial Real Est. Finance (ARI), Zoetis (ZTS), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Akorn (AKRX), Align Technology (ALGN), Amarin (AMRN), Ares Capital (ARCC) and BIOLINERX LTD/S (BLRX).

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Kezar Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (5.06%), BlackRock Inc. (4.41%), EcoR1 Capital LLC (3.05%), Victory Capital Management Inc. (2.41%), Vanguard Group Inc. (2.09%) and Cowen Inc. (1.79%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Morningside Venture Investment and Vassiliki Economides. View Institutional Ownership Trends for Kezar Life Sciences.

KZR stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, EcoR1 Capital LLC, Cowen Inc., Cowen Inc., Citadel Advisors LLC and Vanguard Group Inc.. View Insider Buying and Selling for Kezar Life Sciences.

KZR stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Wells Fargo & Company MN, Bank of New York Mellon Corp, A.R.T. Advisors LLC and Acadian Asset Management LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Morningside Venture Investment and Vassiliki Economides. View Insider Buying and Selling for Kezar Life Sciences.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $4.87.

Kezar Life Sciences has a market capitalization of $93.21 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.View Additional Information About Kezar Life Sciences.

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com/.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]